drugset / Trial / NCT05651932
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).
Timeline
- Start
- 2023-02-22
- Primary completion
- 2027-12-31
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carfilzomib | Other / unclassified | — | Intravenous |
| Subject | KTX-1001 | Small molecule | — | Oral |
| Subject | Mezigdomide | Small molecule | — | — |
| Subject | Pomalidomide | Other / unclassified | — | Oral |
| Background | Dexamethasone | Small molecule | — | Oral |